Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 0.97 |
| ▸ | HTR2A | P28223 | 5/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.97 |
| ▸ | HTR2C | P28335 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL41765 | 1.00 | LMNA (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL28759733 | 1.00 | LMNA (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL15719828 | 0.98 | LMNA (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL34282 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL17004048 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL29350100 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL6118138 | 0.98 | SLC6A4 (1.00) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL29040915 | 0.97 | SLC6A4 (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL27657924 | 0.97 | SLC6A4 (0.97) | LMNAMAPTPMP22SMN1; SMN2KDM4E | |
| Imipramine SCHEMBL3002670 | 0.95 | SLC6A4 (0.94) | LMNAMAPTPMP22SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7040 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| US-4505909-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1985-03-19 | — | — | US | claimed |
| US-4370324-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1983-01-25 | — | — | US | claimed |
| EP-0048023-A2 | Composition for treating and preventing irritation of the eyes | Bernstein, Joel E., M.D. (US) | 1982-03-24 | — | — | EP | claimed |